Skip to main content
NEXALIS THERAPEUTICS LTD logo

NEXALIS THERAPEUTICS LTD — Investor Relations & Filings

Ticker · NX1 ISIN · AU0000456733 ASX Professional, scientific and technical activities
Open in API
Filings indexed 505 across all filing types
Latest filing 2026-05-25 Regulatory Filings
Country AU Australia
Listing ASX NX1

About NEXALIS THERAPEUTICS LTD

https://nexalistherapeutics.com/

Nexalis Therapeutics Ltd focuses on the discovery and development of innovative small molecule therapies for the treatment of chronic inflammatory and autoimmune diseases. The company utilizes a proprietary drug discovery platform to target specific biological pathways, including the NLRP3 inflammasome, which is implicated in the progression of various systemic and neurodegenerative conditions. By developing highly selective and potent modulators, the organization aims to address significant unmet medical needs in patient populations suffering from debilitating inflammatory disorders. Research and development efforts are centered on translating complex biological insights into clinical-stage therapeutic candidates designed to improve patient outcomes and quality of life through precision targeting of immune system dysregulation.

Recent filings

Filing Released Lang Actions
Suspension from Quotation 2 pages 209.5KB
Regulatory Filings Classification · 90% confidence The document is an ASX market announcement regarding the voluntary suspension of the company’s securities under Listing Rule 17.2. It is a compliance/regulatory notice rather than a financial report, board change, or other specific filing type. Therefore it best fits into the general Regulatory Filings (RNS) category.
2026-05-25 English
Trading Halt 2 pages 212.6KB
Regulatory Filings Classification · 90% confidence The document is an ASX Market Announcement notifying a trading halt request for Nexalis Therapeutics Ltd. It is a regulatory announcement relating to continuous disclosure obligations and does not contain substantive financial statements, management commentary, or official report content. This fits the fallback “Regulatory Filings” category for general compliance/regulatory notices.
2026-05-21 English
Phase 1 IRX-616a Last Patient Last Dose 2 pages 128.4KB
Regulatory Filings Classification · 85% confidence The document is a corporate press release announcing the completion of dosing in a Phase 1 clinical trial. It contains no financial statements, earnings metrics, or regulatory filings like 10-K/10-Q, nor is it a management presentation or investor deck. It is an operational update about trial milestones rather than a financial report or call transcript. This does not fit specific categories like Earnings Release, Interim/Quarterly Report, or M&A Activity. Therefore, it falls under the fallback category for miscellaneous regulatory announcements: RNS (Regulatory Filings).
2026-05-13 English
Director Appointment/Resignation 5 pages 334.7KB
Board/Management Information Classification · 95% confidence The document is a public announcement from Nexalis Therapeutics Ltd regarding the resignation of one director and the appointment of another, effective 12 May 2026. It contains no substantive financial data or earnings details; instead, it is a change in board composition. Although it includes attached ASX Appendix 3X and 3Z notices (director interest disclosures), the primary purpose is the board/management change. This fits the Board/Management Information category.
2026-05-12 English
Mar26 Quarterly Activities Report 5 pages 173.7KB
Interim / Quarterly Report Classification · 95% confidence The document is a quarterly activities report for the period ended 31 March 2026, providing detailed updates on clinical trial progress, corporate changes, capital management including a placement and entitlement offer, cash flow, and operational updates. It contains substantive financial data such as cash outflows, capital raises, and clinical development costs. The document is comprehensive and longer than 5,000 characters, indicating it is a full report rather than a brief announcement. The content aligns with the characteristics of an Interim / Quarterly Report, which includes financial statements or substantive financial data and analysis for a period shorter than a full fiscal year. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2026-04-29 English
Mar26 Appendix 4C Cash Flow Report 5 pages 264.5KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B' and contains detailed quarterly cash flow statements including operating, investing, and financing activities for the quarter ended 31 March 2026. It includes actual financial data such as cash flows, financing facilities, and reconciliations. The document is over 11,000 characters, indicating it is a substantive report rather than a brief announcement. The content aligns with a quarterly financial report rather than an annual report or earnings release. The presence of detailed cash flow statements and notes confirms it is an Interim / Quarterly Report (IR).
2026-04-29 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.